Eisai Files Agreement With Generic Drugmakers

Law360, New York (October 12, 2007, 12:00 AM EDT) -- Toyko-based drug company Eisai Co. Ltd. has reached a sort of detente with generic drugmakers Mutual Pharmaceuticals Company, Inc. and United Research Laboratories Inc. in a patent dispute over the billion-dollar Alzheimer's treatment Aricept.

Judge Esther Salas signed off on the stipulation and order Wednesday, approving an agreement which says that URL/Mutual will not sell a generic product containing the active ingredient of Aricept, donepezil hydrochloride in the United States until one of three conditions occur.

Either URL/Mutual must give Eisai written notice of its intent...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.